Crinetics Pharmaceuticals, Inc.
$33.09
+0.98%Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -6.7).
Valuation inputs: P/E -6.7, earnings yield N/A, momentum +1.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -46.9%, ROIC -48.9%).
Profitability stack: net margin -60.5%, ROE -46.9%, ROIC -48.9%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +12.6%, momentum +1.0%, net margin -60.5%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Crinetics Pharmaceuticals, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Crinetics Pharmaceuticals, Inc. Fair Value Envelope
Crinetics Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Crinetics Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Crinetics Pharmaceuticals, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Crinetics Pharmaceuticals, Inc. Street Expectations Map
Wall Street analysts project that CRNX stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 85.83, with estimates ranging from a low of 67.00 to a high of 105.00.
The consensus 1-year price target stands at 85.83, with estimates ranging from a low of 67.00 to a high of 105.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Crinetics Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have sold $10.06M worth of CRNX shares, with no buying activity reported.
3 Months
0
0.00
95.6K
3.80M
-3.8M
-$3.80M
3-6 Months
0
0.00
12.2K
522.81K
-523K
-$523K
6-9 Months
0
0.00
30.1K
1.33M
-1.3M
-$1.33M
9-12 Months
0
0.00
139.0K
4.40M
-4.4M
-$4.40M
Top Buyers
No buying activity
Top Sellers
Knight Jeff E.
Officer: Chief Dev. & Operating Officer
$3.64M
Betz Stephen F.
Officer: Chief Scientific Officer
$3.14M
Pizzuti Dana
Officer: Chief Med And Dev Officer
$1.70M
Fust Matthew K
Director
$716K
Schilke Tobin
Officer: Chief Financial Officer
$266K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $10.06M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
CRNX has not reported any dividend yield values in the available annual periods.
crnx Dividend History
Learning Layer
Related Guides
Build conviction on CRNX by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.